PepGen’s DM1 Bet Runs Into An FDA Hold And Dilution Fears
PepGen (PEPG) is a clinical-stage biotech focused on its lead program PGN-EDODM1 for myotonic dystrophy type 1 (DM1). The company's stock performance is highly volatile and tied to clinical progress, regulatory outcomes, and financing events, including a recent FDA partial clinical hold and an …